Institutions for persons with disabilities that the mortality risk increases exponentially through fatal overdoses in the event of discontinuation or withdrawal of opioid substitution therapy is criticised as dangerous inaction. Due to the availability – considerably increased through the Darknet – of hitherto completely unknown highly dangerous synthetic designer drugs, which is confirmed by the State Office of Criminal Investigation, the current development is very critical. There were eleven predominantly young drug-related deaths in Carinthia in 2017. In the summer of 2017, under the leadership of Gabriele Fischer, university professor and an internationally recognised addiction expert, the NPM established a working group with members from all of the commissions, in which both AOB staff and a former recipient of opioid substitution therapy were involved. The task of this working group was to systematise existing observations on outpatient and inpatient institutions and facilities for persons suffering from addiction, to name structural human rights problem areas that occurred several times and to develop scenarios for the NPM approach on future visits. The working group completed their activities at the end of October 2017 after holding three meetings. Based on this, members of this working group will form a commission that will work on specific areas of focus throughout Austria. XX  Those suffering from addiction must have free and quick access to treatment programmes. Needs-based, top quality treatment programmes based on scientific standards must thus be guaranteed in the inpatient and in outpatient sector. XX  The adequate treatment of comorbid disorders and illnesses has to be an integrative component of such treatment programmes in after-care facilities. XX  Relapses must be seen as a part of substance use disorders that is inherent in crises and require an in-depth multidisciplinary therapeutic approach. XX  Professional action-oriented expertise on assessing and predicting suicidal tendencies must be applied before therapy is (involuntary) discontinued. Evidence must be provided that the affected person has been informed of the increased mortality risk caused by discontinuing therapy. XX  Follow-up care facilities must implement standardised crisis and discharge management with functioning interfaces to better quality care services in hospitals. 99